Loading…
← CockpitCompetitor Analysis › 300401.SZ Zhejiang Garden Biopharmaceutical Co.,Ltd.Open in the cockpit ↗

Zhejiang Garden Biopharmaceutical Co.,Ltd.300401.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Zhejiang maker of vitamin D3 and its derivatives, a major global supplier to supplement and food industries.

≈ A Chinese vitamin-D3 ingredient supplierMomentum neutral 48
Mkt cap
$922M
US dollars, full cap
Free float
63%
of shares outstanding
$/day
$26.5M
20-day average traded
Fwd P/E
22.9×
forward earnings
ROIC−WACC
-0.0 pp
WACC 8.0%
Hurdle
-4 pp
Req g minus delivered
Next earnings
133 days
31 Mar 2027
Close · CNYCN¥11.54
1D+0.6%
1W-7.1%
1M-8.3%
3M-26.4%
6M-14.1%
YTD-23.7%
1Y-15.3%
ATR %4.8%
52w lowhigh50.8% off high

What Zhejiang Garden Biopharmaceutical does

Zhejiang maker of vitamin D3 and its derivatives, a major global supplier to supplement and food industries.

Makes vitamin D3 from lanolin, a wax recovered from sheep's wool, and sells it in bulk, so earnings follow D3 prices, which depend on how much the few big producers make. Its calcifediol line (25-hydroxy D3), used in animal feed, is a more specialised product that fetches a higher price per tonne.

In one line: A Chinese vitamin-D3 ingredient supplier.

Products and services

  • Vitamin D3
  • 25-hydroxyvitamin D3 and derivatives
  • Cholesterol/lanolin extraction

Customers

  • Supplement makers
  • Food and animal feed companies

Where it sits in the supply chain

  • Nutrition ingredients
  • Vitamins
  • Vitamin D3 and derivatives

What could go right

  • Global VDS/supplement demand growth

What could go wrong

  • Commodity vitamin D3 price cycles

Moat: narrow (scale, process know-how). One of the world's larger vitamin D3 producers with integrated extraction and synthesis capacity.

Headquarters: Shaoxing, Zhejiang, China · Employees: 1,163

Named competitors

Zhejiang Garden Biopharmaceutical at a glance

Size Zhejiang Garden Biopharmaceutical (300401.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $922M, the 2314th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥11.54 on 18 Nov 2026.

Performance Over six months the shares fell 14.1%, against -20.9% for the median peer and -20.0% for the China market (cap-weighted) — 8th highest of 20 in its peer set.

Growth Revenue grew 2.4% over the last twelve months (peer median +11.3%); the operating margin is 23.6% (peer median 7.1%).

Valuation It trades at 22.9× forward earnings against a peer median of 23.0× (5th cheapest of 9).

Price implies For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -4 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 0.0 points below its cost of capital (8.0% WACC).

Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).

Relative performance

7510012515021 May 202621 Aug 202618 Nov 2026300401.SZ 85Peer median 81
Six months, rebased to 100: Zhejiang Garden Biopharmaceutical against the median of its 20 peers (local-currency closes).

Zhejiang Garden Biopharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥1.27BCN¥1.23BCN¥1.24BCN¥1.09BCN¥1.41B
Revenue growth—0%+13%-23%—
Gross profitCN¥696MCN¥641MCN¥679MCN¥616MCN¥895M
EBITDAn/aCN¥536MCN¥472MCN¥303MCN¥458M
Net incomeCN¥239MCN¥305MCN¥309MCN¥192MCN¥384M
Free cash flowCN¥131MCN¥117M-CN¥13.3M-CN¥84.6M-CN¥1.99M
Capital expenditureCN¥319MCN¥362MCN¥480MCN¥245MCN¥380M
Total debtCN¥1.88BCN¥2.03BCN¥2.11BCN¥2.11BCN¥884M

Quarterly statements and history in the cockpit →

Zhejiang Garden Biopharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-25%0%+25%0392001795MLTX688177IMTX25956002526004220024376885536035382005AKTS3002946887594565PGHL300401.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Zhejiang Garden Biopharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+200%+400%20×40×0392001795603538STAR20053002944565300401.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Zhejiang Garden Biopharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

-10%0%+10%+20%+30%0%20%0392001795600252002437688553603538STAR20050005974565PGHL300401.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Zhejiang Garden Biopharmaceutical is the large dot.

Zhejiang Garden Biopharmaceutical competitors and peer comparison

Head to head with its named competitors (300401.SZ vs DSFIR.AS vs 002001.SZ vs BAS.DE)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Zhejiang Garden Biopharmaceutical 300401.SZ$922M-14%+2%24%22.9×9.1%
DSM-Firmenich DSFIR.AS$27.5B+47%-45%8%28.6×23.7%
Zhejiang NHU 002001.SZ$11.8B-22%+11%33%9.7×-8.3%
Basf BAS.DE$50.1B0%-4%7%15.8×5.7%

How Zhejiang Garden Biopharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Zhejiang Garden Biopharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure300401.SZPeer medianRank in peer set
1-month return-8.3%-10.0%10th highest of 21
6-month return-14.1%-20.9%8th highest of 20
Distance from 52-week high-50.8%-46.6%9th lowest of 21
Revenue growth (TTM)+2.4%+11.3%9th lowest of 18
Operating margin23.6%7.1%3rd highest of 18
Forward P/E22.9×23.0×5th cheapest of 9
Growth the price implies (Req g, 7 yrs)9.1%7.7%6th most demanding of 12
Growth delivered (Del g)+13.4%+4.9%4th highest of 12
Hurdle (Req g minus delivered)-4.3 pp+2.8 pp5th least demanding of 12
ROIC minus cost of capital-0.0 pp-2.0 pp6th highest of 15

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Zhejiang Garden Biopharmaceutical 300401.SZChina$922M-14%+2%24%22.9×9.1%+13.4%
Oscotec 039200.KSSouth Korea$923M-32%+510%59%50.2×-10.2%+18.1%
Lotus Pharmaceutical 1795.TWTaiwan$921M-37%+67%21%9.8×-3.7%+13.8%
MoonLake Immunotherapeutics MLTXUnited States$918M-37%n/an/an/an/an/a
Bio-Thera Solutions 688177.SSChina$929M-23%+24%-44%n/an/an/a
Immatics IMTXUnited States$913M-46%-44%-589%n/an/an/a
Genfleet Therapeutics (Shanghai) 2595.HKHong Kong$912M-42%-55%-457%n/an/an/a
Guangxi Wuzhou Zhongheng 600252.SSChina$936M-10%-43%-42%n/a10.3%-13.7%
KPC Pharmaceuticals 600422.SSChina$940M-6%-41%-10%n/an/an/a
Harbin Gloria Pharmaceuticals 002437.SZChina$941M-9%-16%13%n/a7.7%-6.9%
Sichuan Huiyu Pharmaceutical 688553.SSChina$904M-28%+14%7%n/a19.4%-6.0%
Ningbo Menovo Pharmaceutical 603538.SSChina$945M-48%+19%9%42.3×11.6%+4.9%
Strides Pharma Science STAR.NSIndia$946M-17%+11%14%15.9×17.6%+7.8%
SSY 2005.HKHong Kong$948M+8%-4%12%12.5×2.3%-0.5%
Aktis Oncology AKTSUnited States$895M-15%+337%-837%n/an/an/a
Northeast Pharmaceutical 000597.SZChina$895M-14%-6%3%n/a-7.6%-0.7%
China Resources Boya Bio-pharmaceutical 300294.SZChina$959M-21%-27%-19%21.4×n/an/a
BeBetter Med 688759.SSChina$960M-58%n/an/an/an/an/a
Latigo Biotherapeutics LTGOUnited States$882Mn/an/an/an/an/an/a
Nxera Pharma 4565.TJapan$974M+46%+24%14%25.8×17.7%+27.3%
Procter & Gamble Health PGHL.NSIndia$979M+3%+13%31%24.5×5.6%+9.3%

Questions

Who are Zhejiang Garden Biopharmaceutical's main competitors?
Named competitors: DSM-Firmenich (DSFIR.AS), Zhejiang NHU (002001.SZ), BASF (BAS.DE). The cockpit's measured peer set (industry) also includes Oscotec (039200.KS), Lotus Pharmaceutical (1795.TW), MoonLake Immunotherapeutics (MLTX), Bio-Thera Solutions (688177.SS), Immatics (IMTX), Genfleet Therapeutics (Shanghai) (2595.HK).
Is Zhejiang Garden Biopharmaceutical expensive compared with its peers?
On forward p/e it trades at 22.9× against a peer median of 23.0×, 5th cheapest of 9 in its peer set. For today's price to make sense, revenue must grow about 9% a year for seven years (Req g). Recent delivered growth is +13%, so the hurdle is -4 pp: the price already allows for a slowdown.
How has Zhejiang Garden Biopharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -14.1% against -20.9% for the median peer; over one year -15.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.